A Tumor-Specific Cascade-Activating Smart Prodrug System for Enhanced Targeted Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapeutics

Background:

• Developing targeted cancer therapies with reduced systemic toxicity is a critical challenge.
• Smart prodrug systems offer potential for localized drug activation and enhanced efficacy.

Purpose of the Study:

• To design and evaluate a tumor-specific, cascade-activating smart prodrug system (ApG4/LDCs) for enhanced cancer treatment.
• To engineer a G-quadruplex (G4)-modulated DNA vehicle for improved drug delivery and stability.

Main Methods:

• Fabrication of a DNA vehicle functionalized with a G4-binding fluorescent ligand.
• Conjugation of ligand-drug conjugates (LDCs) to the DNA vehicle.
• In vitro and in vivo evaluation of the prodrug system's cascade activation, drug release, and antitumor efficacy.

Main Results:

• The engineered DNA vehicle demonstrated high affinity for G4 structures and enhanced nuclease resistance.
• ApG4/LDCs successfully generated reactive oxygen species (nitric oxide, superoxide anion, peroxynitrite) in response to the tumor microenvironment.
• The prodrug system exhibited significant tumor-specific accumulation, controlled drug release, and potent antitumor activity with reduced damage to normal tissues.

Conclusions:

• The developed ApG4/LDCs system represents an innovative strategy for precision cancer therapy.
• Cascade activation and self-reinforcement mechanisms enable effective tumor targeting and destruction.
• This approach holds promise for advancing targeted drug delivery and minimizing off-target effects in cancer treatment.